GeneFerm Biotechnology Co Ltd (1796) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$1.45 Million ≈ $45.65K USD) by net assets (NT$794.03 Million ≈ $25.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of GeneFerm Biotechnology Co Ltd to measure how much of total assets are equity-financed.
GeneFerm Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 1796 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
GeneFerm Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cengild Medical Berhad
KLSE:0243
|
0.008x |
|
Environmental Clean Technologies Ltd
AU:ECT
|
-0.043x |
|
Hung Chou Fiber Ind Co Ltd
TW:1413
|
0.023x |
|
Namhwa Industrial Co. Ltd
KQ:111710
|
-0.006x |
|
MINDMAZE THERAPEUTICS HOLDING SA
SW:MMTX
|
N/A |
|
Lake Victoria Gold Ltd.
V:LVG
|
-0.033x |
|
Bowim S.A.
WAR:BOW
|
0.032x |
|
Toplus Global Co Ltd
TWO:3522
|
0.184x |
Annual Cash Flow Conversion Efficiency for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of GeneFerm Biotechnology Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see GeneFerm Biotechnology Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$788.18 Million ≈ $24.83 Million |
NT$8.09 Million ≈ $254.88K |
0.010x | -95.18% |
| 2023-12-31 | NT$892.84 Million ≈ $28.13 Million |
NT$190.31 Million ≈ $6.00 Million |
0.213x | +44.64% |
| 2022-12-31 | NT$830.77 Million ≈ $26.17 Million |
NT$122.43 Million ≈ $3.86 Million |
0.147x | -1.82% |
| 2021-12-31 | NT$747.66 Million ≈ $23.56 Million |
NT$112.23 Million ≈ $3.54 Million |
0.150x | +5.41% |
| 2020-12-31 | NT$396.19 Million ≈ $12.48 Million |
NT$56.42 Million ≈ $1.78 Million |
0.142x | +825.46% |
| 2019-12-31 | NT$954.50 Million ≈ $30.07 Million |
NT$14.69 Million ≈ $462.72K |
0.015x | -84.79% |
| 2018-12-31 | NT$416.51 Million ≈ $13.12 Million |
NT$42.14 Million ≈ $1.33 Million |
0.101x | -47.83% |
| 2017-12-31 | NT$314.95 Million ≈ $9.92 Million |
NT$61.08 Million ≈ $1.92 Million |
0.194x | -- |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more